Home > Insider Trading > Filing (0000899243-22-029295)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1832038	Adagio Therapeutics Inc.	ADGI	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1807489	M28 Capital Management Lp	700 Canal Street, 2Nd Floor Stamford CT 06902		No	No	No	Yes
1830496	Marc Elia	C/O Adagio Therapeutics, Inc. 1601 Trapelo Road, Suite 178 Waltham MA 02451		Yes	No	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-08-17	1,000,000	$4.04	7,398,250	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2022-08-18	1,265,549	$4.31	8,663,799	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2022-08-19	584,451	$4.62	9,248,250	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Footnotes

The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $3.96 to $4.15.
The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $3.90 to $4.50.
The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $4.33 to $4.70.
The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
This Form 4 is filed by M28 Capital Management LP ("M28 Capital Management") and Marc Elia ("Mr. Elia") with respect to securities held by certain funds and accounts for which M28 Capital Management serves as investment manager. Mr. Elia is the Chief Investment Officer of M28 Capital Management and the Managing Member of M28 Capital Management GP LLC, the general partner of M28 Capital Management. Mr. Elia also serves on the Board of Directors of the Issuer. The Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.